Clinical trials: Fat; Liver
Familial Partial Lipodystrophy
Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients
Lipodystrophies are rare disorders characterized by selective loss of adipose tissue and predisposition to insulin resistance and its metabolic complications.
- Trial name
- NCT02430077
- Testing
- Obeticholic Acid
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Abhimanyu Garg
Severe Hypertriglyceridemia (sHTG), Hypertriglyceridemia
A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial to assess the efficacy and safety of weekly subcutaneous DR10624 injection in adult patients with severe hypertriglyceridemia (sHTG).
- Trial name
- NCT07693777
- Testing
- DR10624 Injection
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Nonalcoholic Steatohepatitis
Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis
The purpose of this study is to determine whether cenicriviroc is effective and safe in the treatment of nonalcoholic steatohepatitis (NASH) in adult participants with liver fibrosis.
- Trial name
- CENTAUR (NCT02217475)
- Testing
- Cenicriviroc
- Where
- 91 sites in United States, Australia and 8 more
- Volunteers
- 289 people
- Sponsor
- Tobira Therapeutics, Inc.
Mediterranean Diet
Mediterranean Diet Treatment for NAFLD
Treatment for Nonalcoholic Fatty Liver Disease (NAFLD) is through lifestyle modification consisting of caloric restriction and exercise, with an emphasis on weight loss.
- Trial name
- NCT04415112
- Testing
- Mediterranean Diet, Low Fat Diet
- Where
- Turkey (Türkiye)
- Volunteers
- 45 people
- Sponsor
- Antalya Training and Research Hospital
Nonalcoholic Steatohepatitis
Digoxin for Patients With Non-alcoholic Steatohepatitis (NASH)
The purpose of this study is to assess if digoxin is safe and efficacious in treating patients with non-alcoholic steatohepatitis (NASH) within the approved target range of 0.7 to 1 ng/ml.
- Trial name
- NCT04216693
- Testing
- Digoxin tablet
- Where
- China
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
NAFLD, Insulin Resistance
Effects of Phytosterol Supplementation on Liver Function and Inflammatory Status in Patients With Nonalcoholic Fatty Liver Disease
Non-alcoholic fatty liver disease (NAFLD) is considered one of the most common chronic liver diseases worldwide, it recently became a worldwide problem with high morbidity which requires further attention.
- Conditions
- NAFLD, Insulin Resistance, Metabolic Syndrome, Obesity
- Trial name
- NCT06697977
- Testing
- phytosterols
- Where
- Jordan
- Volunteers
- 27 people
- Sponsor
- University of Jordan
Diabetes Mellitus, Type 2
Fasted Exercise Training in Type 2 Diabetes
This study compares aerobic exercise training performed before breakfast (i.e., in the fasted state) to similar training performed after breakfast in people with type 2 diabetes. Training will take place over 16 weeks.
- Trial name
- FED (NCT03908281)
- Testing
- Fasted Exercise, Postprandial Exercise
- Where
- Canada
- Volunteers
- 20 people
- Sponsor
- University of Alberta
Non-Alcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver
European Paediatric Non-Alcoholic Fatty Liver Disease Registry (EU-PNAFLD)
The EU-PNAFLD (The European Paediatric NALFD Registry) will be a network composed of European centres involved in the care of children with NAFLD, and will include Hepatologists, Endocrinologists, and Scientists, supported by…
- Conditions
- Non-Alcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver, Non-alcoholic Steatohepatitis
- Trial name
- EU-PNAFLD (NCT04190849)
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 2,000 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Diabetes
Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon
Insulin resistant states are characterized by hepatic lipoprotein (VLDL) particle overproduction. Numerous hormonal and nutritional factors are known to influence hepatic lipoprotein particle production, including insulin and…
- Trial name
- Glucagon (NCT01155206)
- Testing
- glucagon
- Where
- Canada
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- University Health Network, Toronto
Non-Alcoholic Fatty Liver Disease
Pharmacoeconomic Evaluation of the Cost/effectiveness Ratio of Physical Exercise on Non-alcoholic Fatty Liver Disease
Physical inactivity and poor dietary habits are associated with an increased risk of obesity and chronic disease (World Health Organization, 2019; Glanz and Bishop, 2010).
- Trial name
- NCT06026293
- Where
- Italy
- Volunteers
- 58 people
- Sponsor
- Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis
Non-Alcoholic Steatohepatitis
A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
The purpose of this sub-study of MB130-045 is to determine the pharmacokinetic effects, pharmacodynamic effects, efficacy and safety of BMS-986036 20 mg QD in subjects with Non-alcoholic Steatohepatitis (NASH)
- Trial name
- NCT03400163
- Testing
- BMS-986036
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Bristol-Myers Squibb
Fatty Liver
Omega 3 Supplementation in Children With Non Alcoholic Fatty Liver
this is a prospective, interventional, open-label, randomized study on the efficacy of omega 3 fatty acids supplementation in Egyptian children with non-alcoholic fatty liver disease who had been selected from nutrition and…
- Trial name
- omega 3 (NCT04281121)
- Testing
- omega 3 fatty acids
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Metabolic Dysfunction Associated Fatty Liver Disease
Effect of High Protein Diet on Hepatic Steatosis in Patients With MAFLD
MAFLD is a growing problem in India. Its pathophysiology is complex, but focused on abnormal substrate handling due to mitochondrial dysfunction reflecting as metabolic inflexibility. Nutrition is the cornerstone of management.
- Trial name
- NCT06749704
- Testing
- High protein diet, Normal Protein diet
- Where
- India
- Volunteers
- 140 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Non-alcoholic Fatty Liver Disease
Semaglutide in Nonalcoholic Fatty Liver Disease
The goal of this clinical trial is to test the therapeutic effect of Semaglutide in NAFLD and its sequelae in obesity and/or type 2 diabetes mellitus.
- Trial name
- NCT05813249
- Testing
- Rybelsus Oral Product, Ozempic Injectable Product, Tocopherol and/or Actos
- Where
- Egypt
- Volunteers
- 180 people
- Sponsor
- Zagazig University
Safety and Tolerability
A First in Human Study to Evaluate the Safety, Tolerability and PK of GB1211 in Healthy Subjects
This was a Phase 1, randomized, double-blind, placebo-controlled, first-in-human study in which the safety, tolerability, and pharmacokinetics of orally administered GB1211 will be evaluated in healthy adult subjects and adult…
- Trial name
- NCT03809052
- Testing
- GB1211
- Where
- United Kingdom
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Galecto Biotech AB
Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis
The Olmsted NAFLD Epidemiology Study (TONES)
Researchers are assessing the prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) in the population and assembling a well-characterized cohort of adults with NAFLD and NASH to validate…
- Trial name
- NCT04365855
- Testing
- Magnetic Resonance Elastography, Blood draw, Liver biopsy
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- Mayo Clinic
Fatty Liver, Diabetes Mellitus, Type 2
Effects of Ginger on Nonalcoholic Fatty Liver Disease in T2DM
The investigators want to evaluate the effects and safety of ginger in treatment of nonalcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM).
- Trial name
- GinLivDM (NCT02289235)
- Testing
- Ginger
- Where
- Iran
- Volunteers
- 76 people
- Sponsor
- Shiraz University of Medical Sciences
Non-Alcoholic Fatty Liver Disease
Serum Adiponectin as an Early Marker for Renal Impairment in Patients With Non-alcoholic Fatty Liver Disease.
Early detection of renal impairment in patients with non-alcoholic fatty liver disease and its correlation with serum Adiponectin level.
- Trial name
- NCT05106049
- Testing
- serum Adiponectin
- Volunteers
- 90 people
- Sponsor
- Assiut University
Fatty Liver
Metformin for the Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)
The purpose of this study is to find out if Metformin is safe and useful in the treatment of NAFLD.
- Trial name
- NAFLD (NCT00736385)
- Testing
- Glucophage (Metformin)
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Duke University
Obesity
Interventional Strategy in Tackling Emerging Non-alcoholic Fatty Liver Disease in Childhood Obesity
The goal of this clinical trial is to investigate the effects of tocotrienol-rich fraction vitamin E supplementation on liver enzymes in overweight and obese children with non-alcoholic fatty liver disease as compared to placebo.
- Trial name
- NCT05905185
- Testing
- Tocotrienol-rich fraction vitamin E (TRF)
- Where
- Malaysia
- Volunteers
- 29 people
- Sponsor
- National University of Malaysia
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.